Vivid Dx

Vivid Dx is a University of Oxford spin-out developing a culture-free diagnostics platform for rapid pathogen identification and antimicrobial susceptibility testing directly from blood samples.

The system combines Raman spectroscopy, microfluidics, and deep learning to deliver species-level pathogen identification in 30 minutes and phenotypic antibiotic susceptibility results in three hours.

The company has secured £4m in lead investment from Oxford Science Enterprises and a UKRI Biomedical Catalyst grant.